Friday, January 07, 2022

Fauci’s strategy Causing ‘Thousands of People’ to Die Each Month

While promoting the use of masks and vaccines to fight the coronavirus, Dr. Anthony Fauci and many U.S. health officials have discouraged the use of therapeutics.

In a conversation with his father Ron Paul, Republican Sen. Rand Paul said Fauci’s strategy is causing thousands of needless deaths every month.

“I think Fauci is of the philosophy that vaccines are incredibly successful and are the way to go versus therapeutics, for example,” Paul said.

“As the AIDS epidemic came up, he wanted to develop a vaccine. There’s nothing wrong with that.” Of course, this turned out to be unsuccessful — a vaccine for AIDS has still not been created.

In Paul’s eyes, Fauci did not learn from his mistake as he led the response to the coronavirus pandemic.

“I would venture to say that thousands of people die in our country every month now from COVID because he’s de-emphasized the idea that there are therapeutics,” he said.

While Paul’s claim may be unverifiable, it is correct that the Biden administration has hindered the availability of therapeutics to treat COVID-19.

In August, CBS News reported that the CDC had issued an advisory warning against the use of ivermectin to treat COVID-19. It said there was “insufficient data” to show the anti-parasite drug could treat the virus.

Ivermectin had already been approved by the FDA to treat conditions like head lice and rosacea in humans. The CDC said the drug was “generally safe and well tolerated” as a prescription for those issues.

However, the CDC’s warning against ivermectin as a COVID-19 treatment led to widespread disparaging of the drug. Establishment media outlets spoke out against its use, and doctors refused to prescribe it even as a last resort.

The FDA has not approved the use of ivermectin as a treatment for COVID-19


Mum woke from 28-day Covid coma after being treated with Viagra

A nurse fighting for her life in a 28-day Covid coma was saved after colleagues used Viagra to treat her.

Monica Almeida, 37, was just 72 hours from her ventilator being turned off when medics had the idea to use the erectile dysfunction drug, reports The Sun.

The level of oxygen the mum-of-two needed dropped by half and her condition improved after a week - meaning she made it home for Christmas.

Monica has now praised the quick-thinking doctors for using the drug, which helped opened up her airways.

The specialist respiratory nurse, from the UK, said: “I had a little joke with the consultant after I came round because I knew him.

“He told me it was the Viagra, I laughed and thought he was joking, but he said ‘no, really, you’ve had a large dose of Viagra’. “It was my little Christmas miracle.”

Monica, who treated Covid patients while working for NHS Lincolnshire, tested positive for the disease in October.

The double-jabbed mum had lost her sense of taste and smell and was coughing up blood by day four of her diagnosis.

After her oxygen levels dropped the next day, she went to hospital but was discharged with a prescription and no treatment.

Within just two hours of being home, Monica woke up unable to breathe and was rushed to Lincoln County Hospital where she went straight to the resuscitation room.

Medics battled to restore her oxygen levels to normal but her condition deteriorated and she was taken to ICU.

She was placed in a coma on November 16 with her condition so severe, her parents were told to fly from Portugal to England to say their goodbyes.

Monica said: “I could have been gone at just 37 years old, but I suppose I was a bit of a monkey and kept on fighting.”

With the prognosis looking bleak, doctors decided to use the unusual treatment to help Monica.

The brave Covid victim emerged from her coma on December 14 and was allowed to return home on Christmas Eve.

Viagra has previously been banded around as a possible way to treat Covid patients as the little blue pill dilates blood vessels and opens the airways.

Scientists are carrying out tests to determine whether it can be used in the same way as inhaling nitric oxide, which can boost oxygen levels in the blood.

Viagra can be given to Brit coronavirus patients if they have agreed to be in a study to try experimental drugs.

Monica said: “It was definitely the Viagra that saved me. “Within 48 hours it opened up my airways and my lungs started to respond.

“If you think how the drug works, it expands your blood vessels.

“I have asthma and my air sacs needed a little help.”

The mum is now recovering at her home with her husband Artur and two sons aged nine and 14.

She is now urging people to get the vaccine after being told she would have died if she hadn’t been jabbed.

Covid booster jabs offer the best chance to get through the pandemic, health officials have repeatedly said.

Monica said: “There are people out there saying the vaccine has killed people. I’m not denying there are people who react and get poorly with the vaccine, but when we look at the amount of deaths we have in unvaccinated people there is a big message there to have your jab.

“It does worry me, especially in Lincolnshire, that people are against having the vaccine.

“I never expected at 37 years of age to get as ill as I did. I never thought this would happen to me and I want people to take it more seriously.”


Active ingredient in magic mushrooms could help treat mental health disorders including PTSD, research suggests

Scientists say that small doses of the psychedelic drug psilocybin, found in 'magic' mushrooms are not only good at easing disorders resistant to treatment but they also have no short or long-term side effects in healthy people.

Researchers in a study led by the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London, found that the drug can be given safely in doses of either 10mg or 25mg to up to six patients.

The report, in partnership with COMPASS Pathways, is an essential first step for experts to prove the safety and feasibility of drug psilocybin as a treatment alongside talking therapies for a range of conditions including treatment-resistant depression (TRD) and PTSD.

It is the first drug to go head-to-head with the traditional and often ineffective treatments on the market.

Early research hailed the mushroom as a promising treatment but no human trials have been conducted until now.

It is the first trial of its kind to thoroughly investigate the magic of the mushroom.

A sample of 89 participants who had not used psilocybin within a year were recruited to take part in the trial. Then 60 people were picked at random to receive either 10mg or 25mg of the drug in a controlled lab environment. The patients received one-to-one support from trained psychotherapists after the doses were administered.

A placebo drug was given to the remaining 29 participants who acted as the control group and were also given psychological support.

The participants were closely monitored for six to eight hours and they were then followed up for 12 weeks.

During this time, they were assessed to track the number of possible changes, including sustained attention, memory, planning, as well as their ability to process emotions.

Dr James Rucker, a clinical scientist from the National Institute for Health Research, was the study's lead author. He said: 'This rigorous study is an important first demonstration that the simultaneous administration of psilocybin can be explored further.

'If we think about how psilocybin therapy (if approved) may be delivered in the future, it's important to demonstrate the feasibility and the safety of giving it to more than one person at the same time, so we can think about how we scale up the treatment.'

Dr Rucker, who is also an honorary consultant psychiatrist at South London and Maudsley NHS Foundation Trust added: 'This therapy has promise for people living with serious mental health problems, like treatment-resistant depression (TRD) and PTSD.

'They can be extremely disabling, distressing and disruptive, but current treatment options for these conditions are ineffective or partially effective for many people.'

There were no suggestions that either of the psilocybin doses had any short or long-term negative effects on the participant and no one withdrew from the study.

Professor Guy Goodwin the chief medical officer at COMPASS Pathways, said: 'This study was an early part of our clinical development programme for COMP360 psilocybin therapy.

'It explored the safety and feasibility of simultaneous psilocybin administration, with one to one support, in healthy participants, and provided a strong foundation to which we have now added positive results from our Phase IIb trial in 233 patients with TRD, and from our open-label study of patients taking SSRI antidepressants alongside psilocybin therapy.

'We are looking forward to finalising plans for our phase three programme, which we expect to begin in Q3 2022.'

Since this study was conducted, the researchers have completed phase two of the study, which has explored the efficacy and safety of psilocybin in people living with TRD and PTSD, and are now analysing their findings.

This study was published in The Journal of Psychopharmacology.




No comments: